Security Snapshot

COLLEGIUM PHARMACEUTICAL INC - NOTE 2.875% 2/1 Institutional Ownership

CUSIP: 19459JAC8

13F Institutional Holders and Ownership History from Q1 2024 to Q2 2026

Latest Period

Q1 2026

Institutions Reporting

11

Principal

$239,921,000

Price (% of par)

116.05%

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Principal change
+$18,069,500
Market value change
+$11,766,272
Number of holders
11
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • 19459JAC8 - COLLEGIUM PHARMACEUTICAL INC - NOTE 2.875% 2/1 is tracked under CUSIP 19459JAC8.
  • 11 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 11 to 0 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $276,700,466 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 11 institutions filings for Q1 2026.

Open SEC evidence

Security key

19459JAC8

Latest holder period

Q1 2026

13F holders

11

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 11 institutional investors reported holding $239,921,000 in principal (par value) of COLLEGIUM PHARMACEUTICAL INC - NOTE 2.875% 2/1.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
10
Latest
Q1 2026
Rows shown
1-10 of 10
Period Principal Value Change Price (% of par) (Median) Investors
2026 Q2 $0 $0 -$8,633,754 0
2026 Q1 $239,921,000 $276,700,466 +$11,766,272 116.05% 11
2025 Q4 $223,668,500 $316,120,070 +$37,661,592 141.04% 18
2025 Q3 $232,365,607 $262,147,060 +$3,032,485 118.26% 14
2025 Q2 $252,522,607 $277,265,835 -$9,056,409 107.65% 14
2025 Q1 $259,426,607 $282,455,513 +$356,625 107.73% 19
2024 Q4 $250,703,607 $271,591,541 -$2,439,434 105.17% 19
2024 Q3 $242,103,727 $305,287,034 +$21,239,070 126.2% 18
2024 Q2 $228,151,727 $268,334,805 -$4,307,514 110.61% 16
2024 Q1 $230,363,607 $305,680,689 +$295,038,969 124.92% 19
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .